Edinburgh-based biotechnology company Cytomos has raised £5 million to scale up production of its cell analysis technology.

The oversubscribed funding round was led by existing investors Archangels with participation from Old College Capital, Scottish Enterprise and British Business Bank.

The investment will help Cytomos drive sales of its first commercial product Celledonia, built on its cell-analysis technology platform AuraCyt, which is already generating market traction.

Celledonia is a benchtop cell analyser which aims to significantly enhance single-cell analysis, potentially transforming biological drug discovery, development processes and biologics manufacturing.

Cytomos employs 21 staff, largely based at its new premises in Roslin, and expects to add another four staff over the next year.

The firm has its sights set on establishing a foothold in North America and has a pipeline of trials planned.

Sarah Hardy, director and head of new investments at Archangels, said: “Cytomos has gone from strength to strength, achieving commercialisation earlier this year marks a critical inflection point for the business.

“With new premises secured and a robust plan to derisk the supply chain, we’re looking forward to helping David and the team scale their operations and secure access to new markets.”

Cytomos CEO David Rigterink said: “Successfully raising £5 million within a difficult market has been a huge boost for the business. The result is testament to the team’s hard work in delivering our first commercial product with international early adopters.

“Cytomos now has the right building blocks in place to scale quickly, establish a foothold in the US, and continue developing our single cell analysis technology to support advancements in biological drug development and manufacturing automation.”